Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects.

What Was Tested

This randomized controlled trial looks at Dietary Proteins.

The purpose of this study was to evaluate if a dietary supplement of soy protein, isoflavones, and cotyledon fiber (Abalon) affects cardiovascular risk markers, blood glucose, and insulin levels in type 2 diabetic subjects.

Who Took Part

The abstract describes 2 subjects taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Twenty type 2 diabetic subjects participated in a crossover trial.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Dietary Proteins and who got the comparison, which limits bias.

As a double-blind Dietary Proteins study, the assignments were hidden from both participants and investigators until the end.

Some subjects received a placebo instead of Dietary Proteins, giving a reference point.

Each person switched between Dietary Proteins and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Apolipoprotein B-100, Apolipoproteins B, Blood Glucose, Cardiovascular Diseases, Cholesterol, HDL, Cholesterol, LDL and Diabetes Mellitus, Type 2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Dietary Proteins in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Diabetes care), a journal based in United States.

More context: all human trials.